Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.38 EUR | -1.16% | -5.13% | -25.98% |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.98% | 1.94B | B | ||
-1.78% | 41.71B | B | ||
+47.70% | 41.56B | A | ||
+4.01% | 39.74B | B- | ||
-15.14% | 25.61B | C | ||
+3.16% | 24.26B | B- | ||
-24.08% | 18.55B | B | ||
-2.67% | 11.93B | C+ | ||
+24.76% | 11.93B | C+ | ||
+7.01% | 10.91B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GLPG Stock
- Ratings Galapagos NV